ASRS

Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases at the 2023 ASRS annual meeting.

Michael Ip, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why they're vital to a modern view of ophthalmology.

Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Carl Danzig, MD, shared the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS meeting.

Shawn Kavoussi, MD, shared insights from his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, shared how new techniques are expanding the options for deep learning in ophthalmology.

Matthew R. Starr, MD, discusses how secondary lens techniques have changed over time.

Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study At the 2023 ASRS meeting in Seattle, Washington.

At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Richard B Rosen, MD, who is presenting New 'MacGyver-Inspired' Endolaser Option for Chandelier-Assisted Scleral Buckles at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.

The research saw that new-onset full-thickness macular holes (FTMHs), especially those resulting from blunt ocular trauma, might close spontaneously without the need for a surgical intervention.

The research saw that new-onset full-thickness macular holes (FTMHs), especially those resulting from blunt ocular trauma, might close spontaneously without the need for a surgical intervention.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

In presentations at the ASRS 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

In presentations at the American Society of Retina Specialists 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

Cindy Cai, MD, who is presenting Health disparities in lapses in diabetic retinopathy care at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this presentation.

During presentations at the ASRS 41st Annual Meeting in Seattle, Apellis noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis, and no events were reported in clinical trials.

During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.

Michael Ip, MD, shared his perspective on the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why he thinks they are valuable topics to understand and review for retina specialists.

Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.

Diana Do, MD, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University, spoke with our team about the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema at the 2023 ASRS meeting in Seattle, Washington.

This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.

At the 2023 ASRS meeting in Seattle, Washington, Diana Do, MD joined our team to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema.